R&D In The IRA Era: Takeda Opts Not To Develop Zasocitinib For Lupus

The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.

Key Takeaways

Takeda will not develop its oral TYK2 inhibitor zasocitinib for systemic lupus erythematosus despite strong scientific rationale and a business case.
President of R&D Andy Plump said the decision was impacted by the timeline for zasocitinib, an oral small molecule drug, to face US Medicare drug price negotiations under the IRA.
Takeda is also behind its rival, Bristol Myers Squibb, whose TYK2 inhibitor Sotyktu is in Phase III studies for SLE.

Takeda Pharmaceutical Co. Ltd

Playing a part in the decision was the US Medicare drug price negotiation program under the Inflation Reduction Act (IRA), passed by the Biden administration in 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

19 May 2025

• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

05 May 2025

• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

16 May 2025

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.